Literature DB >> 22529186

High expression of octamer-binding transcription factor 4A, prominin-1 and aldehyde dehydrogenase strongly indicates involvement in the initiation of lung adenocarcinoma resulting in shorter disease-free intervals.

Lourdes Cortes-Dericks1, Domenico Galetta, Lorenzo Spaggiari, Ralph Alexander Schmid, Golnaz Karoubi.   

Abstract

OBJECTIVES: The increasing relevance of the cancer stem cell (CSC) hypothesis and the impact of CSC-associated markers in the carcinogenesis of solid tumours may provide potential prognostic implications in lung cancer. We propose that a collective genetic analysis of established CSC-related markers will generate data to better define the role of putative CSCs in lung adenocarcinoma (LAC).
METHODS: Sixty-four paired tumour and non-tumour biopsies from LAC patients were included in this study. Using the quantitative reverse transcriptase-polymerase chain reaction, we assessed the expression profiles of established CSC-related biomarkers: octamer-binding transcription factor 4 (OCT4A), CD133, aldehyde dehydrogenase (ALDH), BMI-1, ATP-binding cassette subfamily G, member 2 (ABCG2), SRY (sex-determining region Y)-box 2 (SOX2) and uPAR, and evaluated their relation to clinicopathological parameters and disease prognosis.
RESULTS: All of the above-mentioned CSC-related markers were detectable in both tumour and corresponding normal tissues. Importantly, expression levels of OCT4A, CD133, BMI-1, SOX2 and uPAR were significantly higher (OCT4A, P = 0.0003; CD133, P = 0.002; BMI-1, P = 0.04; SOX2, P = 0.0003; uPAR, P = 0.03) in the tumour compared with those in the non-tumour tissues. By contrast, the quantities of ACBG2 and ALDH were markedly reduced (ACBG2, P = 0.0006; ALDH, P = 0.007) in the tumour relative to those in the normal biopsies. Using multivariate analysis, elevated ALDH and CD133 revealed significant associations in tumour stage (ALDH, P = 0.03; CD133, P = 0.007) and differentiation (ALDH, P = 0.03; CD133, P = 0.018). We observed that ALDH and OCT4A were associated with nodal status (ALDH, P = 0.05; OCT4A, P = 0.03) having lower mRNA levels in tumours with lymph node metastasis, N+, compared with that in N0. High OCT4A levels were significantly correlated with tumour size of <3 cm, decrease in tumours >3 cm (P = 0.03). Kaplan-Meier correlation analyses, showed that OCT4A and CD133 were correlated to short disease-free intervals (OCT4A, P = 0.047; CD133, P = 0.033) over a period of 29 months.
CONCLUSIONS: Our study reveals that CSC-associated markers: OCT4A, CD133 and ALDH are involved in the initial phase of carcinogenesis of LAC, and can be used as predictors of early stage LAC and poor disease-free intervals. In addition, this work validates the relevance of the CSC hypothesis in LAC.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22529186     DOI: 10.1093/ejcts/ezs170

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  17 in total

1.  Prognostic value of ALDH1 expression in lung cancer: a meta-analysis.

Authors:  Wei Huo; Min Du; Xinyan Pan; Xiaomin Zhu; Zhimin Li
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Wnt signaling regulation of stem-like properties in human lung adenocarcinoma cell lines.

Authors:  Yan Zhang; Xueyan Zhang; Jinsu Huang; Qianggang Dong
Journal:  Med Oncol       Date:  2015-04-04       Impact factor: 3.064

3.  Clinicopathological and prognostic significance of Oct-4 expression in patients with non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Shuang-Jiang Li; Jian Huang; Xu-Dong Zhou; Wen-Biao Zhang; Yu-Tian Lai; Guo-Wei Che
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

4.  Clinicopathological significance of CD133 in lung cancer: A meta-analysis.

Authors:  Yaoxi Tan; Bo Chen; Wei Xu; Weihong Zhao; Jianqing Wu
Journal:  Mol Clin Oncol       Date:  2013-09-30

5.  Expression of Oct-4 is significantly associated with the development and prognosis of colorectal cancer.

Authors:  Huan Zhou; Y U Hu; Weipeng Wang; Yong Mao; Jingjie Zhu; Bin Zhou; Jing Sun; Xueguang Zhang
Journal:  Oncol Lett       Date:  2015-05-26       Impact factor: 2.967

Review 6.  Lung cancer stem cells: a biological and clinical perspective.

Authors:  Ana Koren; Helena Motaln; Tanja Cufer
Journal:  Cell Oncol (Dordr)       Date:  2013-07-31       Impact factor: 6.730

7.  Acquisition of Cancer Stem Cell-like Properties in Human Small Airway Epithelial Cells after a Long-term Exposure to Carbon Nanomaterials.

Authors:  Chayanin Kiratipaiboon; Todd A Stueckle; Rajib Ghosh; Liying W Rojanasakul; Yi Charlie Chen; Cerasela Zoica Dinu; Yon Rojanasakul
Journal:  Environ Sci Nano       Date:  2019-05-24

Review 8.  Pluripotency transcription factors in lung cancer-a review.

Authors:  Sylwia Sławek; Krzysztof Szmyt; Maciej Fularz; Joanna Dziudzia; Maciej Boruczkowski; Jan Sikora; Mariusz Kaczmarek
Journal:  Tumour Biol       Date:  2015-11-18

Review 9.  Reporters of Cancer Stem Cells as a Tool for Drug Discovery.

Authors:  Amrutha Mohan; Reshma Raj R; Gayathri Mohan; Padmaja K P; Tessy Thomas Maliekal
Journal:  Front Oncol       Date:  2021-04-22       Impact factor: 6.244

Review 10.  Lung cancer stem cells: Molecular features and therapeutic targets.

Authors:  Sandeep Singh; Srikumar Chellappan
Journal:  Mol Aspects Med       Date:  2013-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.